North Star Asset Management Inc. Takes $980,000 Position in Pfizer Inc. $PFE

North Star Asset Management Inc. purchased a new stake in shares of Pfizer Inc. (NYSE:PFE) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 40,700 shares of the biopharmaceutical company’s stock, valued at approximately $980,000.

Other institutional investors also recently bought and sold shares of the company. Godfrey Financial Associates Inc. bought a new stake in Pfizer during the 4th quarter valued at approximately $26,000. Keb Asset Management LLC bought a new position in shares of Pfizer in the 2nd quarter worth approximately $26,000. HFM Investment Advisors LLC raised its position in shares of Pfizer by 61.0% in the 4th quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 427 shares in the last quarter. Evolution Wealth Management Inc. lifted its stake in shares of Pfizer by 132.2% in the 1st quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 566 shares during the period. Finally, Abound Financial LLC bought a new stake in shares of Pfizer during the fourth quarter valued at approximately $31,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on PFE shares. UBS Group reaffirmed a “neutral” rating and issued a $27.00 price target on shares of Pfizer in a research note on Wednesday, May 27th. Bank of America lowered their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. HSBC downgraded shares of Pfizer from a “buy” rating to a “hold” rating and reduced their target price for the stock from $32.00 to $28.00 in a research report on Monday, July 6th. BMO Capital Markets decreased their price target on shares of Pfizer from $34.00 to $30.00 and set an “outperform” rating for the company in a research note on Monday, July 13th. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $27.00 price target on shares of Pfizer in a research report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $28.28.

Pfizer Stock Performance

Pfizer stock opened at $27.95 on Friday. Pfizer Inc. has a twelve month low of $23.58 and a twelve month high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $159.31 billion, a P/E ratio of 36.78 and a beta of 0.34. The stock’s 50 day moving average is $25.55 and its 200 day moving average is $26.30.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The business had revenue of $15.03 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter in the previous year, the business earned $0.78 earnings per share. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities research analysts predict that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Friday, July 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.2%. The ex-dividend date of this dividend is Friday, July 24th. Pfizer’s payout ratio is currently 226.32%.

More Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer and BioNTech’s XFG-adapted 2026–2027 COMIRNATY vaccine for adults 65 and older and people ages 5–64 with underlying conditions that increase the risk of severe COVID-19. Shipments to U.S. pharmacies, hospitals and clinics are beginning immediately, supporting seasonal vaccine revenue and confirming Pfizer’s continuing role in infectious-disease prevention. Reuters FDA approval article
• Positive Sentiment: Pfizer and Valneva’s Lyme disease vaccine candidate, PF-07307405, reached an additional regulatory milestone after its European Marketing Authorization Application was validated. If approved, the product could help diversify Pfizer’s vaccine portfolio beyond COVID-19. Pfizer COVID and Lyme vaccine milestones article
• Neutral Sentiment: Pfizer announced several clinical-development updates, including an early-stage autoimmune trial for PF-08154225, a Phase 1 study evaluating easier injection delivery for tilrekimig, a tucatinib continuation study and a post-marketing Xalkori study. These programs may strengthen the pipeline, but they remain too early or incremental to affect near-term valuation. Pfizer pipeline update
• Negative Sentiment: The updated COVID vaccine is aimed at older and high-risk patients, creating a substantially smaller addressable market than broad-based vaccination campaigns. That limits the likely revenue lift even though approval and immediate distribution are favorable developments. Pfizer updated COVID shot article
• Negative Sentiment: BioNTech’s failed colorectal-cancer vaccine trial pressured sentiment across the mRNA sector. Pfizer was relatively insulated because the setback involves BioNTech’s oncology program rather than a Pfizer-specific clinical failure, but the broader result reinforces investor concerns about the limits of mRNA technology outside infectious disease. BioNTech colorectal cancer trial article
• Negative Sentiment: Commentary continues to question Pfizer’s dividend sustainability because its payout ratio exceeds 100% and much of the turnaround case depends on cost reductions and growth targets that do not begin meaningfully until later in the decade. These concerns can cap enthusiasm despite Pfizer trading near its 52-week high.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.